STEROID SPARING AGENTS AND METHODS OF USING SAME
This invention relates generally to methods of treating inflammatory bowel diseases (IBD), asthma, Crohn's Disease (CD), multiple sclerosis (MS), rheumatoid arthritis (RA), graft versus host disease (GVHD), host versus graft disease, and various spondyloarthropathies, comprising administering a steroid-sparing effective amount of an immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions.
1 . A method of reducing and/or eliminating a need for steroid treatment in a subject with inflammatory bowel disease comprising administering to the subject a steroid sparing agent in a steroid sparing effective amount, wherein the steroid sparing agent is an anti-α4-immunoglobulin.
2 . The method of claim 1 , wherein the subject is a human.
3 . The method of claim 1 , wherein the steroid sparing agent is a monoclonal antibody or an immunologically active fragment of a monoclonal antibody.
4 . The method of claim 3 , wherein the monoclonal antibody is a chimeric antibody, a human antibody, a genetically engineered antibody, or a bispecific antibody.
5 . The method of claim 4 , wherein the antibody or an immunologically active fragment thereof binds to α4β1 integrin.
6 . The method of claim 4 , wherein the antibody or an immunologically active fragment thereof binds to α4β7 integrin.
7 . The method of claim 5 , wherein the antibody is a humanized antibody or an immunologically active fragment thereof.
8 . The method of claim 7 , wherein the humanized antibody is natalizumab or an immunologically active fragment thereof.
9 . The method of claim 8 , wherein natalizumab is administered parenterally to the subject in need thereof.
10 . The method of claim 8 , wherein natalizumab is administered chronically to the subject in need thereof.
11 . The method of claim 9 , wherein the parenteral administration results in an effective blood level of natalizumab of at least about 1 ng/mL in said subject.
12 . The method of claim 9 , wherein the effective blood level of natalizumab is about 1 ng/mL in said subject.
13 . The method of claim 1 , wherein the steroid sparing agent is administered chronically to the subject.
14 . The method of claim 13 , wherein the chronic administration of the steroid sparing agent is weekly or monthly over a period of at least one year.
15 . The method of claim 1 , wherein the steroid sparing reagent is administered in an amount effective to permit the subject to be tapered from steroid therapy.
16 . The method of claim 15 , wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
17 . The method of claim 15 , wherein the anti-α4 immunoglobulin is administered to said subject in an amount of about 2 mg/kg to about 8 mg/kg.
18 . The method of claim 15 , wherein the subject is refractory, intolerant or dependent on steroids.
19 . The method of claim 18 , wherein the subject requires a therapeutically effective amount of steroids that is less than would be required in the absence of administering the anti-α4 immunoglobulin.
20 . The method of claim 18 , wherein the subject is: a) a patient that is unresponsive or intolerant to treatment with immunosuppressive agents; b) a patient that is unresponsive, intolerant or dependent on treatment with steroids; or c) a patient that is a combination of a) and b).
21 - 83 . (canceled)